Spiralling healthcare costs and productivity losses from the global obesity crisis far outstrip the cost of new weight-loss drugs, according to a report, which also calls on governments to prioritise prevention by promoting a healthy diet and exercise.
In the UK, Germany and the Netherlands, there is a clear economic case for these medications, the report says, as the annual cost of the diabetes drug Ozempic is lower than the cost of additional healthcare needed by people with obesity. The cost of the weight-loss injection Wegovy is higher, but still dwarfed by the overall economic cost to society of obesity, according to the research by ING Bank, shared with the Guardian.
